Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Completed 3

Sponsor Class

NIH 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3Thoracic 1Genitourinary 1Dermatologic 1Breast 1

Conditions

Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Solid Tumours 5Melanoma 5Neurofibromatosis 1 4Lung Neoplasms 4Rectal Neoplasms 3Neoplasm Metastasis 3Colorectal Neoplasms 3Colonic Neoplasms 3Breast Neoplasms 3Biliary Tract Neoplasms 3Neurofibroma, Plexiform 2Uveal Melanoma 1Solid Tumors 1Renal Insufficiency 1Primary Myelofibrosis 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Muscle Invasive Bladder Cancer 1Locally Advanced or Metastatic Solid Tumors 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Kidney Neoplasms 1Healthy Volunteers Pharmacokinetic Study 1Gallbladder Neoplasms 1Disease Progression 1Cholangiocarcinoma 1Advanced Non Small Cell Lung Cancer 1Advanced Cancer 1Adult Solid Neoplasm 1

Interventions

Oxaliplatin 31Fluorouracil 31Leucovorin 29Irinotecan 23Cetuximab 20Bevacizumab 16Capecitabine 13Gemcitabine 11pembrolizumab 8Folfox protocol 7Cisplatin 7Carboplatin 7Paclitaxel 6Nivolumab 6Cyclophosphamide 6trifluridine tipiracil drug combination 5cediranib 5Erlotinib Hydrochloride 5adagrasib 4Ipilimumab 4IFL protocol 4Floxuridine 4Bortezomib 4veliparib 3trametinib 3sargramostim 3poly ICLC 3binimetinib 3Trifluridine 3Sorafenib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Colonic Neoplasms × AZD 6244 × Clear all
NCT00600496 2026-05-27

A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)

AstraZeneca

Phase 1 Completed
140 enrolled
BreastDermatologicGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Colonic Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasms

NCT01287130 2019-12-17

AZD6244 With Cetuximab for Solid Tumors and Colorectal Cancer

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
10 enrolled
Gastrointestinal

Colonic Neoplasms, Colorectal Neoplasms

NCT01217450 2014-05-29

Selumetinib and Cetuximab in Treating Patients With Refractory Solid Tumors

National Cancer Institute (NCI)

Phase 1 Completed
33 enrolled
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡